KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Short term Debt (2016 - 2025)

AbbVie (ABBV) has disclosed Short term Debt for 14 consecutive years, with $2.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Short term Debt fell 63.27% to $2.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 billion, a 63.27% decrease, with the full-year FY2025 number at $2.5 billion, down 63.27% from a year prior.
  • Short term Debt was $2.5 billion for Q4 2025 at AbbVie, up from $2.0 billion in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $12.6 billion in Q2 2024 to a low of $1.0 million in Q4 2022.
  • A 5-year average of $5.2 billion and a median of $5.1 billion in 2023 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: tumbled 99.99% in 2023, then soared 1019200.0% in 2024.
  • AbbVie's Short term Debt stood at $14.0 million in 2021, then crashed by 92.86% to $1.0 million in 2022, then skyrocketed by 719000.0% to $7.2 billion in 2023, then fell by 5.38% to $6.8 billion in 2024, then tumbled by 63.27% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Short term Debt are $2.5 billion (Q4 2025), $2.0 billion (Q3 2025), and $2.0 billion (Q2 2025).